HOME >> BIOLOGY >> NEWS
Novel Two-Antibody Strategy To Fight Cancer Awarded Patent

Researchers at the University of Pennsylvania Medical Center today were awarded patent number 5,824,311 for a new technology that has shown the potential in laboratory studies to cure breast and other major cancers linked to certain abnormal genes.

Broadly viewed, the approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.

The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a two-protein receptor complex thought to be involved in stimulating the uncontrolled growth of a number of dangerous cancers, including those of the breast and the pancreas. Instructions for producing the p185 protein in the cell are encoded by a gene known as neu.

The recently approved anti-breast-cancer drug Herceptin also acts on the receptor produced by the neu gene but brings only one antibody to bear on it. Experiments in rodent models, however, showed that a two-antibody strategy was significantly more powerful.

"In our two-antibody studies, we were able to achieve cures of tumors as opposed to simply reducing tumor growth," says Mark I. Greene, MD, PhD, a professor of pathology and laboratory medicine in whose laboratory the work was conducted. "In our experience, a single antibody against the receptor only diminishes the growth of tumor cells, whereas two antibodies disable the receptor so effectively that the cells perish."

Receptor proteins are convoluted structures with many sites -- called epitopes -- to which a wide array of antibodies can bind. It is possible for some of these sites not to be involved in the activity of the protein. Also, antibodies that bind in different ways to the same site can limit each other's effectiveness. Signif
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
20-Oct-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel Two Antibody Strategy Fight Cancer Awarded Patent

(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... the stability of today,s largest ice sheets in Greenland and ... ago, for example when Earth was going through a ... high sea level due to ice sheet collapse at that ... if the world,s largest ice sheets collapsed in the past, ... progressively warming world. , However, a new groundbreaking study ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
(Date:5/21/2013)... PathoGenetix, Inc., a commercial-stage developer of ... today that it has successfully identified and strain typed ... from the Centers for Disease Control and Prevention (CDC) ... findings are detailed in a poster presented ... Microbiology in Denver on Monday. , The 250 E. ...
(Date:5/20/2013)... Ras Al Khaimah, UAE (PRWEB) May 21, 2013 ... and private equity consultancy specializing in “game-changing” life science ... appointment of Ms. Dalia Dergham to its International Project ... certain to bring even greater multi-cultural depth to Grace ... more projects around the globe. , Ms. Dergham holds ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... , Md. and BALTIMORE , May ... (BHI), a regional private-public partnership focusing on commercializing ... funding in Central Maryland , ... M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI ... National Heart, Lung and Blood Institute (NHLBI). ...
Breaking Biology Technology:New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
Cached News: